Abstract

3521Background: The survival advantage conferred by the addition of cet to FOLFOX chemotherapy was verified in TAILOR, the first prospective, randomized, phase 3 study of the addition of cet to 1L ...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Systemıc Chemotherapy in Colorectal Cancer
Murat Keser ... Olcun Umit Unal
-
Murat Keser, et. al.Murat Keser ... Olcun Umit Unal
30 Oct 2020
Case Report: Marked Survival Advantage of Two Colorectal Cancer Patients with Liver Metastases Treated with Vigil and FOLFOX-6.
Vedin Barve ... Ernest Bognar
Vaccines | VOL. 9
Vedin Barve, et. al.Vedin Barve ... Ernest Bognar
18 Oct 2021

More From: Journal of Clinical Oncology

Paper Title
Journal
Date
Author
Sharing the Burden: The Case for Definitive Local Therapy in Place of Immune Checkpoint Blockade for Patients With a Low-Volume Burden of Metastatic Disease.
Connor Lynch ... Ralph R Weichselbaum
Journal of Clinical Oncology | VOL. -
Connor Lynch, et. al.Connor Lynch ... Ralph R Weichselbaum
22 Jul 2024
Academic Uphill Battle to Personalize Treatment for Patients With Stage II/III Triple-Negative Breast Cancer.
Marleen Kok ... Roberto Salgado
Journal of Clinical Oncology | VOL. -
Marleen Kok, et. al.Marleen Kok ... Roberto Salgado
22 Jul 2024
Stockholm3 in a Multiethnic Cohort for Prostate Cancer Detection (SEPTA): A Prospective Multicentered Trial.
Hari T Vigneswaran ...
Journal of Clinical Oncology | VOL. -
Hari T Vigneswaran, et. al.Hari T Vigneswaran ...
22 Jul 2024
Intratumoral Escherichia Is Associated With Improved Survival to Single-Agent Immune Checkpoint Inhibition in Patients With Advanced Non-Small-Cell Lung Cancer.
Arielle Elkrief ... Chad M Vanderbilt
Journal of Clinical Oncology | VOL. -
Arielle Elkrief, et. al.Arielle Elkrief ... Chad M Vanderbilt
22 Jul 2024
View more papers